Advertisement


Irene M. Ghobrial, MD, on How COVID-19 is Changing the Conduct of Clinical Trials

COVID-19 and Cancer Care

Advertisement

Irene M. Ghobrial, MD, of Dana-Farber Cancer Institute, talks about PROMISE—her screening study for people at high-risk of developing precursor conditions of multiple myeloma­­—and how this and other trials have been altered in the wake of the pandemic, as well as what might be considered a silver lining to the crisis. Filmed March 30, 2020.



Related Videos

COVID-19

Mikkael A. Sekeres, MD, on Cancer Treatment in the Age of COVID-19: Personal Observations

Mikkael A. Sekeres, MD, of the Cleveland Clinic, talks about the ways in which social distancing and viral fears have affected the way he delivers treatment for his patients, as well as the effect on their psyches—and his. Recorded April 10, 2020.

Leukemia
COVID-19

Laura C. Michaelis, MD: In My Experience Question 3

COVID-19
Global Cancer Care

Rafal Dziadziuszko, MD, PhD, on Helping Ease Oncology Patients’ Fears of Contracting COVID-19

Rafal Dziadziuszko, MD, PhD, of the Medical University of Gdansk, discusses the concerns his patients with cancer have about exposure to COVID-19 when they come to his institution for care and how he manages their fears. Filmed April 24, 2020.

COVID-19
Global Cancer Care

Rafal Dziadziuszko, MD, PhD, on Using Telemedicine During the Pandemic: Experience in Poland

Rafal Dziadziuszko, MD, PhD, of the Medical University of Gdansk, talks about the adjustments to cancer care that he and his colleagues have made, how and when they employ telemedicine, and whether the technology could change the future for clinical practice. Filmed April 24, 2020.

Multiple Myeloma
COVID-19

Saad Z. Usmani, MD: In My Experience Question 1

As a result of COVID-19, has your decision model for front-line therapy changed for patients with multiple myeloma who are either transplant-eligible or ineligible?

Recorded April 24, 2020.

Advertisement

Advertisement




Advertisement